204 related articles for article (PubMed ID: 9929505)
1. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
[TBL] [Abstract][Full Text] [Related]
2. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504
[TBL] [Abstract][Full Text] [Related]
3. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
[TBL] [Abstract][Full Text] [Related]
4. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
[TBL] [Abstract][Full Text] [Related]
5. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
6. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans.
Lavrijsen K; Van Houdt J; Van Dyck D; Hendrickx J; Lauwers W; Hurkmans R; Bockx M; Janssen C; Meuldermans W; Heykants J
Drug Metab Dispos; 1990; 18(5):704-10. PubMed ID: 1981724
[TBL] [Abstract][Full Text] [Related]
8. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
10. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
Vyas KP; Kari PH; Prakash SR; Duggan DE
Drug Metab Dispos; 1990; 18(2):218-22. PubMed ID: 1971576
[TBL] [Abstract][Full Text] [Related]
13. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
Remmel RP; Crews BC; Kozak KR; Kalgutkar AS; Marnett LJ
Drug Metab Dispos; 2004 Jan; 32(1):113-22. PubMed ID: 14709628
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
16. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of the anti-angiogenic compound SU5416.
Antonian L; Zhang H; Yang C; Wagner G; Shawver LK; Shet M; Ogilvie B; Madan A; Parkinson A
Drug Metab Dispos; 2000 Dec; 28(12):1505-12. PubMed ID: 11095590
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
Khier S; Gattacceca F; El Messaoudi S; Lafaille F; Deleuze-Masquéfa C; Bompart J; Cooper JF; Solassol I; Pinguet F; Bonnet PA; Bressolle FM
Drug Metab Dispos; 2010 Oct; 38(10):1836-47. PubMed ID: 20660102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
